繁
简
Market+ (iPhone)
Market+ (Android)
Mobile Site
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
Quote Service
Market
Market
Quotes
Quotes
Analysis
Analysis
Commentary
Commentary
Warrants&CBBCs
Warrants&CBBCs
Warrants&CBBCs Overview
Warrants
CBBCs
ETF
ETF
MPF
MPF
Education
Members
Members
About Us
About Us

IPO Plus - IPO

To-be Listed
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
S.F. Holding
06936.HK		 Air Freight & Logistics 32.3-36.3 200 N/A 2024/11/22 2024/11/26 2024/11/27
Jiuyuan Gene
02566.HK		 Biotechnology - Medical Devices 11.48-12.56 200 N/A 2024/11/25 2024/11/27 2024/11/28
Mokingran
02585.HK		 Watch & Jewellery 12-14.4 200 N/A 2024/11/26 2024/11/28 2024/11/29
BASECARE-B (02170.HK)
Summary
We are an innovative platform of genetic testing solutions for assisted reproduction in China, according to Frost & Sullivan. Our PGT-A kit, which screens for aneuploidy, a chromosomal disorder frequently associated with implantation failure in in vitro fertilization, or IVF, in embryos prior to implantation, is the first and only third-generation IVF genetic test kit which has been approved by the NMPA, compare to other PGT-A products based on fluorescence in situ hybridization (FISH) and quantitative polymerase chain reaction (qPCR) technologies. The NMPA registration of our PGT-A kit, in February 2020, as a Class III “innovative medical device,” marked the birth of a regulated third-generation IVF market in China in which we are, to date, the only approved kit maker. There are other PGT-A kits in China that are in the process of applying for the NMPA registration certificate and sold for limited scientific research purposes.

We are developing two other pre-implantation genetic testing, or PGT, products, namely, PGT-M and PGT-SR kits, which, together with our PGT-A kit, would form a complete test kit lineup to occupy the PGT field, all based on next-generation sequencing, or NGS, technologies. We expect to obtain NMPA registration approval for these kits in 2022 and 2024, respectively, which we anticipate would further our dominance in the third-generation IVF genetic test kit market in China, well ahead of potential competition.

Leveraging our core strength in PGT, we have positioned ourselves to become an innovative platform in China's broader reproductive genetics market. We have extended our reach beyond the pre-implantation stage to the prenatal and postnatal stages, and are developing one kit in each stage, which makes us a company in China with a genetic test kit pipeline that covers the full reproductive cycle, according to Frost & Sullivan. Beyond test kits, we have developed a number of innovative devices and instruments that can improve work flow in molecular genetic laboratories with our kits. In addition to our self-developed products, we also distribute DA8600, the only NGS sequencer approved by the NMPA for PGT, on which our test kits are designed to run, and a number of other test kits.

We have pioneered a solution model under which we provide our clients, which are hospitals and reproductive clinics in China offering the relevant assisted reproductive services, with one-stop, customized integrated solutions, including not only consumables (test kits) and hardware devices and instruments but also comprehensive services, such as providing guidance and advice on laboratory design, operation and management, pre-sale and after-sale technical support, on demand based on specific individual needs, to help them establish from scratch, and further enhance, their reproductive genetic testing, analysis and counseling capabilities. Through our comprehensive solutions, we aspire to empower our clients to better serve reproductive patients in China in ways that did not exist before.

Third-generation IVF is only beginning to develop in China. The large population base, growing awareness and acceptance of PGT as part of IVF treatments, and a PGT penetration rate that is significantly lower than that in the United States suggest significant growth potential. Based on our dominant leadership in PGT, we believe we are strategically positioned to serve the larger reproductive genetics medical devices market.

We have strong R&D capabilities based on a clinically driven R&D model to develop one-stop, customized integrated reproductive genetics solutions to address unmet clinical needs in China, tailored to overcome the challenges specific to the Chinese patient population. We focus on developing intellectual property—a combination of patents, copyrights, proprietary know-how and trade secrets—for products and solutions that we believe have mass-market demand potential and clear regulatory pathway visibility. In addition to conducting internal R&D programs, we partner with key business partners in many aspects of our business, such as major hospitals and reproductive clinics in China, global life sciences and biotechnology companies in the industry, such as Thermo Fisher, and academic institutions, such as the Chinese University of Hong Kong. We maintain solid relationships with influential KOLs and physicians in the assisted reproduction medical field and establish joint laboratories with major hospitals and reproductive clinics in China, so that we understand the most acute needs of frontline clinical care. We believe our holistic R&D approach and comprehensive capabilities have been the foundation of our industry position.

We have a dedicated management team with deep industry experience and firm commitment to the reproductive genetics cause, led by our founder and chairman of the Board, Dr. Liang. With over ten years of experience in bioinformatics, Dr. Liang has not only led the development of successful products and technologies in the genetic testing field, but also enjoyed a good reputation in the academic community, having co-published over 20 academic papers in respected scientific journals. Our R&D team has a stable core of industry veterans, including Dr. Liang, who have worked together in the reproductive science industry for almost a decade.

Source: Basecare-B (02170) Prospectus (IPO Date : 2021/01/27)
Listing Market MAIN
Industry Biotechnology
Background H Shares
Major Business Area N/A
Corporate Information
Substantial Shareholders LIANG Bo & Associates (Total share: 33.39%); (H share: 0.00%)
XU Wenbo & Associates (Total share: 6.06%); (H share: 0.00%)
Beijing Zhongcheng Fangyuan Phase II Investment Center (Limited Partnership) (Total share: 5.55%); (H share: 0.00%)
Hillhouse Investment Management, Ltd. (Total share: 4.99%); (H share: 7.26%)
OrbiMed Capital LLC (Total share: 2.97%); (H share: 9.81%)
Directors LIANG Bo (Chairman and General Manager and Co-Chief Financial Officer and Executive Director)
KONG Lingyin (Chief Technology Officer and Executive Director)
JIANG Junchao (Executive Director)
WANG Weipeng (Non-Executive Director)
XU Wenbo (Non-Executive Director)
LING Yang (Non-Executive Director)
KANG Xixiong (Independent Non-Executive Director)
LAM Siu Wing (Independent Non-Executive Director)
YEUNG Shu Biu William (Independent Non-Executive Director)
Company Secretary Chung Ming Fai
Yin Lejun
Principal Bankers Shanghai Pudong Development Bank Co., Ltd.
Solicitors Kirkland & Ellis International
Jingtian & Gongcheng
Auditors KPMG
Registered Office 40th Floor, Dah Sing Financial Centre, 248 Queen’s Road East, Wanchai, Hong Kong
Share Registrars Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No (852) 2862-8628
Internet Address http://www.basecare.cn
Email Address ir@basecare.cn
Tel No (86 400) 188-7878
Fax No
 
SITEMAP
AASTOCKS.com
 
 
Members
 
About Us
Market
Quotes
 
Analysis
News & Research
 
Commentary
 
Warrants&CBBCs
 
Warrants
 
CBBCs
 
US Stocks
Forex
 
Fund
 
MPF
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.